Jordi Ponce: “These tests clarify 90% of cases where conventional histology fails.”

In February took place in Madrid the prestigious Velázquez Medical Cabinet Congress , which brought together important gynecologists and obstetricians from all over Spain. Applications and protocols for biomolecular diagnosis in endometrial cancer has been one of the topics addressed by the Head of the Service of the University Hospital of Bellvitge, Jordi Ponce.

Ponce pointed out that endometrial cancer is characterized by having a good prognosis, with a 5 years survival of 80-85%. However, there are two distinct types of endometrial cancer disease: Type 1, the most common type of tumor has a very good prognosis at early stage. In contrast, type 2 (serous carcinoma and clear cell carcinomas, about 20%) is characterized by more aggressive tumors with poor prognosis.

Regarding its detection, after reviewing standard clinical protocols, Ponce highlighted the role of molecular diagnosis. In this sense, he has spoken about the GynEC-DX test, developed by Reig Jofre. “This test can be performed on an endometrial aspirate. It generates a value indicative of the presence or absence of cancer. The risk of error is less than 1%.”

See full news (Spanish)